OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

Date of occurrence: June 01, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass media: China Times E-Paper Content reported: OBI Pharma (4174) announced the in-licensing of the novel first-in-class small molecule drug TH-3424 from California Threshold Pharmaceuticals. The […]

This article is password protected.

To view the content, please enter your password in the field below